Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP. The main reason for this research study is to compare the effectiveness these drugs at reducing rates of PEP. There have been no studies comparing the effectiveness of these medications in preventing PEP in pediatric patients. You are being asked to take part in this research study because you are scheduled to have an ERCP as part of your medical care.
Age range
6 Months – 21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Post-ERCP Pancreatitis
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Pancreatic Duct Injections
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Native Papilla
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Pancreatic Sphincterotomy
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Opti-Ray Amount
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Therapeutic Pancreatic Duct Stent Placed
Timeframe: 2 weeks
Post-ERCP Pancreatitis: Prophylactic Pancreatic Duct Stent Placed
Timeframe: 2 weeks